

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Garcia, et al.

U.S. Appln. No.: 10/779,543

Filing Date: February 12, 2004

Title: GENE PRODUCTS DIFFERENTIALLY
EXPRESSED IN CANCEROUS CELLS
AND THEIR METHODS OF USE II

Confirmation No.: 8423

Group Art Unit: 1637

Examiner: Bertagna, Angela Marie

TRANSMITTAL UNDER 37 CFR § 1.63 (c) (1)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In response to the Office Communication of December 7, 2011, applicant submits the enclosed supplemental application data sheet, which contains a mailing address for each of the three named inventors as required by 37 CFR 1.63(c)(1).

There are no fees required for this submission. The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: January 6, 2012

By: 
Mei Hong
Agent for Applicant
Registration No.: 55,276

Customer No. 27476
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Corporate Intellectual Property – X-100B
P.O. Box 8097
Emeryville, CA 94662-8097
Tel (510) 923-5413
Fax (510) 655-3542